In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Department of Veterans Affairs 
Mammography Quality Standards Act''.

SEC. 2. MAMMOGRAPHY QUALITY STANDARDS.

    (a) In General.--(1) Subchapter II of chapter 73 is amended by 
adding at the end the following new section:
``Sec. 7319. Mammography quality standards
    ``(a) A mammogram may not be performed at a Department facility 
unless that facility is accredited for that purpose by a private 
nonprofit organization designated by the Secretary. An organization 
designated by the Secretary under this subsection shall meet the 
standards for accrediting bodies established under section 354(e) of 
the Public Health Service Act (42 U.S.C. 263b(e)).
    ``(b) The Secretary, in consultation with the Secretary of Health 
and Human Services, shall prescribe quality assurance and quality 
control standards relating to the performance and interpretation of 
mammograms and use of mammogram equipment and facilities of the 
Department of Veterans Affairs consistent with the requirements of 
section 354(f)(1) of the Public Health Service Act. Such standards 
shall be no less stringent than the standards prescribed by the 
Secretary of Health and Human Services under section 354(f) of the 
Public Health Service Act.
    ``(c)(1) The Secretary, to ensure compliance with the standards 
prescribed under subsection (b), shall provide for an annual inspection 
of the equipment and facilities used by and in Department health care 
facilities for the performance of mammograms. Such inspections shall be 
carried out in a manner consistent with the inspection of certified 
facilities by the Secretary of Health and Human Services under section 
354(g) of the Public Health Service Act.
    ``(2) The Secretary may not provide for an inspection under 
paragraph (1) to be performed by a State agency.
    ``(d) The Secretary shall ensure that mammograms performed for the 
Department under contract with any non-Department facility or provider 
conform to the quality standards prescribed by the Secretary of Health 
and Human Services under section 354 of the Public Health Service Act.
    ``(e) For the purposes of this section, the term `mammogram' has 
the meaning given such term in paragraph (5) of section 354(a) of the 
Public Health Service Act (42 U.S.C. 263b(a)).''.
    (2) The table of sections at the beginning of such chapter is 
amended by inserting after the item relating to section 7318 the 
following new item:

``7319. Mammography quality standards.''.
    (b) Deadline for Prescribing Standards.--The Secretary of Veterans 
Affairs shall prescribe standards under subsection (b) of section 7319 
of title 38, United States Code, as added by subsection (a), not later 
than the end of the 120-day period beginning on the later of--
            (1) the date on which the Secretary of Health and Human 
        Services prescribes quality standards under section 354(f) of 
        the Public Health Service Act (42 U.S.C. 263b(f)); or
            (2) the date of the enactment of this Act.
    (c) Transition.--(1) Subsection (a) of section 7319 of title 38, 
United States Code, as added by subsection (a), shall take effect on 
the date on which standards are prescribed by the Secretary of Veterans 
Affairs under subsection (b) of that section.
    (2) During the transition period, the Secretary of Veterans Affairs 
may waive the requirement of subsection (a) of section 7319 of title 
38, United States Code, as added by subsection (a), to any facility of 
the Department. The Secretary may provide such a waiver in the case of 
any facility only if the Secretary determines, based upon the 
recommendation of the Under Secretary for Health of the Department of 
Veterans Affairs, that during the period such a waiver is in effect for 
such facility (including any extension of the waiver under paragraph 
(3)) the facility will be operated in accordance with standards 
prescribed by the Secretary under subsection (b) of such section to 
assure the safety and accuracy of mammography services provided.
    (3) The transition period for purposes of this section is the six-
month period beginning on the date specified in paragraph (1). The 
Secretary may extend such period for a period not to exceed 90 days in 
the case of any Department facility. Any such extension may be made 
only if the Under Secretary for Health determines that--
            (A) without the extension access of veterans to mammography 
        services in the geographic area served by the facility would be 
        significantly reduced; and
            (B) appropriate steps will be taken before the end of the 
        transition period (as extended) to obtain accreditation of the 
        facility as required by subsection (a) of section 7319 of title 
        38, United States Code, as added by subsection (a).
    (d) Implementation Report.--The Secretary of Veterans Affairs shall 
submit to the Committees on Veterans' Affairs of the Senate and House 
of Representatives a report on the Secretary's implementation of 
section 7319 of title 38, United States Code, as added by subsection 
(a). The report shall be submitted not later than 180 days after the 
date on which the Secretary prescribes the quality standards required 
under subsection (b) of that section.
Department of Veterans Affairs Mammography Quality Standards Act - Prohibits a mammogram from being performed at a Department of Veterans Affairs facility unless the facility is accredited for such purpose by a private nonprofit organization designated by the Secretary of Veterans Affairs.  Requires any such organization to meet the standards for accrediting bodies established under the Public Health Service Act (the Act). 
Directs the Secretary to prescribe quality assurance and control standards relating to performance and interpretation of mammograms and the use of Department mammogram equipment and facilities consistent with requirements of the Act.  Requires the Secretary to provide for an annual inspection of Department mammogram equipment and facilities. Requires any Department mammograms contracted to a non-Department facility or provider to conform to the standards of the Act.  Provides for:  (1) a deadline for the prescribing of standards; (2) transition provisions covering mammograms performed prior to the enactment of this Act; and (3) an implementation report from the Secretary to specified congressional committees.

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Spacefaring Priorities for America's 
Continued Exploration Act'' or the ``SPACE Act''.

SEC. 2. FINDINGS.

    Congress finds the following:
            (1) Russia is not a reliable partner.--(A) Unless Space 
        Shuttle operations are extended beyond 2010, the United States 
        will be heavily reliant on Russia to supply crew and possibly 
        cargo transport services to the International Space Station 
        during the gap period of 2010 through 2015. There will be no 
        other way to fly our astronauts into space during this period.
            (B) The United States should not increase its reliance on 
        Russia to transport American astronauts into space, given the 
        increasingly divergent views and posturing from Russia. Russia 
        opposes the United States plan to base an antimissile radar 
        system in the Czech Republic and interceptor missiles in Poland 
        to deal with the threat posed by the Iranian nuclear weapons 
        and missile programs. Russia also suspended its participation 
        in the Conventional Forces in Europe (CFE) treaty, one of the 
        most significant arms control agreements of the Cold War years. 
        Additionally, Russia continues to arm some of America's most 
        hostile adversaries, Iran and Venezuela. Despite United States 
        objections, Russia sold billions of dollars worth of weapons to 
        the regime of Hugo Chavez in 2006. Such meddling is a possible 
        violation of the Monroe Doctrine and a throwback to the Cold 
        War era. Even more troublesome is the Russian history of 
        weapons trading with Iran. Russia has supplied advanced 
        conventional arms technology, missile technology, and nuclear 
        technologies to this very anti-American regime.
            (2) Russia has abused past nasa cooperation agreements.--
        (A) In the late 1990s, Russia fell short in fulfilling its 
        commitment to the International Space Station.
            (B) The National Aeronautics and Space Administration (in 
        this Act referred to as ``NASA'') was forced to transfer 
        hundreds of millions of dollars to enable the Russians to 
        complete the critical Space Station service module Zvezda, 
        without which the International Space Station could not 
        operate.
            (C) Russia delayed completion of the Zvezda service module 
        for several years. Under the International Space Station 
        agreement, the Russian government had committed to fund as well 
        as build the Zvezda service module. Subsequent transfers from 
        the United States, in order to complete the module, reflect 
        serious Russian mismanagement in the field of space.
            (D) In 2000, while Russia was failing to meet its 
        commitment to the International Space Station, Russia was 
        diverting financial and human resources away from fulfilling 
        its International Space Station commitments in order to keep 
        the Russian's Mir Space Station aloft.
            (E) Russia's past shortcomings in fulfilling commitments to 
        its international space partners should serve as a warning to 
        the United States as we consider increased reliance on Russian 
        space services in the future. It is not prudent for the United 
        States to depend on Russia for access to space given our past 
        experience with this relationship.
            (3) American space science should not be dependent on 
        russian support.--(A) The United States has already invested 
        billions of dollars in the International Space Station program 
        since its inception.
            (B) There is much research of great value being conducted 
        in space, and on the International Space Station, that may 
        yield tremendous gains. Research being conducted on the 
        International Space Station may help scientists back on Earth 
        develop medicines to treat diseases and help us better 
        understand the Earth's climate. Many scientists believe that 
        the microgravity environment of space will enable the 
        development of new drugs, vaccines, and other therapies. 
        Equipment on the International Space Station will monitor 
        stratospheric gases, and investigate ozone chemistry.
            (4) The united states must have assured access to space.--
        (A) To ensure that the United States realizes the dividends 
        from the considerable investment we have made in the 
        International Space Station, we need to ensure continued access 
        to space for our astronauts. However, NASA's plan for transport 
        of crew to and from the International Space Station fails to 
        provide necessary redundancies to provide assured access to 
        space.
            (B) NASA anticipates that the Russian Soyuz spacecraft will 
        be the only vehicle for astronaut crew rotation to the 
        International Space Station after 2010. From 2011 until the 
        planned operation of Orion in 2015, NASA likely has no other 
        option for transporting American astronauts to space other than 
        on Russian vehicles.
            (C) NASA has conceded that without the Space Shuttle, it 
        will be unable to transport the Alpha Magnetic Spectrometer 
        (AMS) to the International Space Station. Scientists involved 
        in the development of the AMS acknowledge that it will enhance 
        scientific discoveries. While the AMS has cost over 
        $1,500,000,000 to develop and build, NASA has stated that the 
        remaining Space Shuttle manifest does not allow for transport 
        of the AMS and that it will not be an option to retrofit 
        another launch vehicle in order to fly it into space. Only by 
        extending Space Shuttle operations beyond 2010 will NASA be 
        able to transport the AMS to the International Space Station. 
        As long as the AMS meets all required standards to verify its 
        validity and justify its transport on the Space Shuttle, NASA 
        should fulfill its obligation to the Department of Energy and 
        our international partners.
            (D) In addition, the Japanese Centrifuge Accommodation 
        Module, which can only fly to the International Space Station 
        on the Space Shuttle, will also be unable to reach the Space 
        Station absent extending Space Shuttle operations.
            (5) A better approach.--(A) Due to NASA's lack of a backup 
        plan for reliance on the Russians for transport of American 
        astronauts to space, the United States needs a better approach. 
        The best approach is the Space Shuttle, a proven, domestic 
        source of space transport for assured access to space, 
        including the International Space Station, for crew and cargo 
        transport.
            (B) With 2 Shuttle missions per year during the human 
        spaceflight program flight gap between Shuttle and Orion, 
        currently scheduled from 2010 through 2015, we can replace our 
        need to rely on the Russians for crew rotation for the 
        International Space Station.
            (C) Savings from replacing Russian transport services to 
        the International Space Station with the Space Shuttle would 
        pay for a portion of the costs for flying 2 Space Shuttle 
        missions per year.
            (D) Only by closing the gap between 2010 and 2015, or until 
        the Orion is operational, will our Nation be able to keep our 
        Nation's highly skilled and critically important spaceworkers 
        and engineers gainfully employed, and mitigate the loss of 
        critical skills.
            (E) By extending Space Shuttle operations, NASA may realize 
        considerable savings by no longer having to pay retention 
        bonuses to critical space workers. But retention bonuses would 
        not be the only added costs associated with the end of Space 
        Shuttle operations when critical skilled workers leave NASA or 
        its contractors. Recruitment incentives for new workers and 
        contract cost increases could also be incurred by NASA since 
        the majority of the Kennedy Space Center's workforce are 
        contractors.
            (F) The success of the Constellation program will depend on 
        having the most skilled and experienced workforce possible. The 
        workforce gap, as currently envisioned by NASA, will jeopardize 
        this. NASA has acknowledged that thousands of critical space 
        workers will lose their jobs in the transition from the Space 
        Shuttle to the Constellation program. Continued operation of 
        the Space Shuttle, but on a reduced flight requirement, while 
        also integrating these workers into the Orion program, is the 
        best way to retain many of these critical workers and skill 
        sets.
            (G) An August 2007 study by the Government Accountability 
        Office, ``NASA Progress Made on Strategic Human Capital 
        Management, but Future Program Challenges Remain,'' stated that 
        ``the agency as a whole faces challenges in recruiting and 
        retaining highly experienced senior-level engineers in certain 
        specialties. NASA's principal workforce challenge will be faced 
        in the transition to the next generation of human space flight 
        systems.''.
            (H) This Act authorizes for NASA additional funding under 
        section 4 to fully restore the appropriation shortfalls in 
        fiscal years 2007 and 2008 compared to the funds that were 
        authorized for NASA. An additional $1,000,000,000 is authorized 
        in section 4(b) to reimburse NASA for the costs incurred by 
        NASA from the Space Shuttle return-to-flight efforts following 
        the Space Shuttle Columbia disaster.

SEC. 3. PROHIBITION ON USE OF RUSSIAN SPACE SERVICES.

    NASA shall not rely solely on the Russian government for astronaut 
transport or cargo resupply services. This prohibition does not apply 
to the current Soyuz emergency escape services for astronauts on the 
International Space Station.

SEC. 4. ADDITIONAL FUNDING FOR NASA.

    (a) Additional Authorization for Fiscal Year 2007 Shortfall.--There 
are authorized to be appropriated to NASA $1,648,000,000, 41.6 percent 
of which shall be for Exploration Systems, and 28.7 percent of which 
shall be available for Space Operations.
    (b) Columbia Return-to-Flight.--There are authorized to be 
appropriated to NASA $1,000,000,000 for emergency funding to reimburse 
for Columbia return-to-flight costs, of which the Exploration Systems 
and Space Operations Accounts shall receive funding at the rate 
proportional to the amounts used to pay the costs associated with the 
Space Shuttle return-to-flight efforts.
    (c) Additional Authorization for Fiscal Year 2008 Shortfall.--There 
are authorized to be appropriated to NASA $1,064,000,000, 41.7 percent 
of which shall be for Exploration Systems.
    (d) Preservation of Funding for Programs.--NASA shall not take any 
funding from its Exploration Systems account or the Constellation 
program in order to fund the continued operation of the Space Shuttle 
program as required in this Act.

SEC. 5. EXTENDING SPACE SHUTTLE OPERATIONS.

    (a) Use of Space Shuttle for Access to Space.--NASA shall fly at 
least 2 Space Shuttle missions per year for crew transport, instead of 
Russian crew and cargo services, for the period of 2010 through 2015, 
or until Orion is operational. There are authorized to be appropriated 
to NASA such sums as may be necessary, in addition to amounts otherwise 
authorized, to carry out this subsection, including for the production 
of more external tanks as may be needed.
    (b) Insufficient Funding.--Except as provided under subsection (c), 
the requirements of this Act shall have effect only to the extent that 
sufficient funding is appropriated, as authorized under subsection (a). 
Sufficient funding is defined as funds required to fully or partially 
comply with the requirements of this Act.
    (c) Report to Congress.--NASA shall report to Congress not later 
than 90 days after the date of enactment of this Act on the specific 
costs and actions needed to extend the operation of the Space Shuttle 
in accordance with this Act.
    (d) Operational Efficiencies.--As soon as possible, but no later 
than March 31, 2011, NASA shall investigate areas of reduced operations 
and enhanced cost savings and implement those that do not impinge the 
safe operation of the Space Shuttle program, including the following:
            (1) The possible retirement of one Space Shuttle orbiter, 
        leaving 2 to remain operational, in a manner that ensures the 
        safe operation of the Space Shuttle program.
            (2) Significantly reducing changes to the design of the 
        Space Shuttle orbiters, in a manner that ensures the safe 
        operation of the Space Shuttle program. This shall include 
        changes to the Space Shuttle software systems.
            (3) Significantly reducing Space Shuttle orbiter 
        configuration operations and payload configuration operations, 
        in a manner that ensures the safe operation of the Space 
        Shuttle program.
            (4) Maximizing the use of shared personnel between the 
        continued operation of the Space Shuttle and Constellation and 
        other NASA programs.
    (e) Facilities.--If conflicts arise in NASA's efforts to allocate 
facilities, personnel, and other resources in order to fly the Space 
Shuttle as well as continue the development of Constellation, then NASA 
shall identify in a report to Congress in advance such conflicts, along 
with recommendations as to how they can be mitigated.

SEC. 6. SHUTTLE RECERTIFICATION.

    Not later than 6 months after the date of enactment of this Act, 
NASA shall define achievable and attainable requirements for operation 
of the Space Shuttle program beyond 2010, as recommended by the 
Columbia Accident Investigation Board. NASA shall transmit these 
requirements to Congress in the form of a report. NASA shall then 
immediately begin the process of satisfying these requirements and 
shall satisfy all requirements no later than March 31, 2010.
Spacefaring Priorities for America's Continued Exploration Act or SPACE Act - Prohibits the National Aeronautics and Space Administration (NASA) from relying solely on the Russian government for astronaut transport or cargo resupply services, except for the current Soyuz emergency escape services for astronauts on the International Space Station.

Authorizes appropriations to NASA for: (1) exploration systems; and (2) emergency funding for Columbia return-to-flight costs.

Requires NASA to fly at least two space shuttle missions per year for crew transport, instead of Russian crew and cargo services, for the period 2010-2015, or until Orion is operational. Authorizes appropriations to carry out such operations. Requires NASA to report to Congress on the specific costs and actions needed to extend the operation of the space shuttle.

Requires NASA, by March 31, 2011, to investigate areas of reduced operations and enhanced cost savings and implement those that do not impinge on the safe operation of the space shuttle program.

Directs NASA to define achievable and attainable requirements for the operation of such program beyond 2010, as recommended by the Columbia Accident Investigation Board. Requires: (1) NASA to report to Congress on such requirements; and (2) NASA to immediately begin satisfying those requirements and to satisfy all of them by March 31, 2010.

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Meth Lab Eradication Act''.

SEC. 2. TRANSFER OF EPHEDRINE, PSEUDOEPHEDRINE, AND PHENYLPROPANOLAMINE 
              TO SCHEDULE V; EXCEPTION FOR LIST I PSEUDOEPHEDRINE 
              PRODUCTS.

    (a) Transfer to Schedule V; Exception.--Section 202(c) of the 
Controlled Substances Act (21 U.S.C. 812(c)) is amended in schedule V--
            (1) by inserting ``(a)'' before ``Any compound''; and
            (2) by adding at the end the following:
    ``(b) Unless specifically excepted or unless listed in another 
schedule, any of the following substances, including their salts, 
optical isomers, and salts of optical isomers:
            ``(1) Ephedrine.
            ``(2) Pseudoephedrine.
            ``(3) Phenlypropanolamine.
    ``(c) Pseudoephedrine, including its salts, optical isomers, and 
salts of optical isomers, is excepted from this schedule when contained 
in a product that--
            ``(1) is in the form of a liquid, liquid capsule, or 
        liquid-filled gel capsule;
            ``(2) does not contain more than 360 milligrams of 
        pseudoephedrine; and
            ``(3) is approved under section 505 of the Federal Food, 
        Drug, and Cosmetic Act.''.
    (b) Conforming Amendments Regarding List I Chemicals.--
            (1) Definition; striking of provisions relating to 
        ephedrine and phenylpropanolamine.--Section 102(34) of the 
        Controlled Substances Act (21 U.S.C. 802(34)) is amended--
                    (A) by striking subparagraphs (C) and (I);
                    (B) by redesignating subparagraphs (D) through (H) 
                as subparagraphs (C) through (G), respectively;
                    (C) by redesignating subparagraphs (J) through (Y) 
                as subparagraphs (H) through (W), respectively; and
                    (D) by moving subparagraphs (N), (Q), and (S) (as 
                so redesignated) two ems to the left.
            (2) List i pseudoephedrine product.--Section 102 of the 
        Controlled Substances Act (21 U.S.C. 802) is amended--
                    (A) in paragraph (34), by amending subparagraph (I) 
                (as redesignated by paragraph (1)(C) of this 
                subsection) to read as follows:
            ``(I) Pseudoephedrine, and its salts, optical isomers, and 
        salts of optical isomers, when contained in a list I 
        pseudoephedrine product (as defined in paragraph (45)).'';
                    (B) by striking paragraph (45) and inserting the 
                following:
    ``(45) The term `list I pseudoephedrine product' means a chemical 
specified in paragraph (34)(I) when contained in a product referred to 
in schedule V(c).''; and
                    (C) in paragraph (46)--
                            (i) in subparagraph (A), by striking ``or 
                        phenylpropanolamine'';
                            (ii) by striking subparagraph (B); and
                            (iii) by redesignating subparagraph (C) as 
                        subparagraph (B).
            (3) Regulated transactions.--The Controlled Substances Act 
        (21 U.S.C. 801 et seq.) is amended--
                    (A) in section 102(a)(39)(A), by amending clause 
                (iv) to read as follows:
                    ``(iv)(I) any transaction in a listed chemical that 
                is contained in a drug that may be marketed or 
                distributed lawfully in the United States under the 
                Federal Food, Drug, and Cosmetic Act (other than a list 
                I pseudoephedrine product) unless--
                            ``(aa) the Attorney General has determined 
                        under section 204 that the drug or group of 
                        drugs is being diverted to obtain the listed 
                        chemical for use in the illicit production of a 
                        controlled substance; and
                            ``(bb) the quantity of the listed chemical 
                        contained in the drug included in the 
                        transaction or multiple transactions equals or 
                        exceeds the threshold established for that 
                        chemical by the Attorney General; or
                    ``(II) any transaction in a list I pseudoephedrine 
                product by a retail distributor, unless the Attorney 
                General has determined under section 204 that the 
                product is being diverted to obtain pseudoephedrine for 
                use in the illicit production of methamphetamine; or''; 
                and
                    (B) in section 204, by striking subsection (e).

SEC. 3. REQUIREMENTS REGARDING LIST I PSEUDOEPHEDRINE PRODUCTS.

    Section 310 of the Controlled Substances Act (21 U.S.C. 830) is 
amended--
            (1) in subsection (b), by striking paragraph (3); and
            (2) by adding at the end the following subsection:
    ``(d) List I Pseudoephedrine Products.--
            ``(1) Requirements regarding retail sales.--Each person who 
        sells at retail a list I pseudoephedrine product shall ensure 
        that sales of such product are made in accordance with the 
        following requirements:
                    ``(A) In offering the product for sale, the person 
                places the product such that customers do not have 
                direct access to the product before the sale is made 
                (commonly known as behind-the-counter).
                    ``(B) The person delivers the product directly to 
                the purchaser, and not through use of the mails or any 
                private or commercial carrier.
                    ``(C) The person does not sell such a product that 
                is in the form of a package that can be further broken 
                down or subdivided into two or more separate and 
                distinct packages.
                    ``(D) The person does not knowingly sell to an 
                individual more than one such product during a 24-hour 
                period.
                    ``(E) The person maintains a written list of sales 
                of such products that identifies the products, the 
                purchasers, and the dates and times of the sales (which 
                list is referred to in this paragraph as the 
                `logbook)').
                    ``(F) The person does not sell such a product 
                unless--
                            ``(i) the prospective purchaser--
                                    ``(I) is 18 years of age or older;
                                    ``(II) presents an identification 
                                card that provides a photograph and is 
                                issued by a State or the Federal 
                                Government; and
                                    ``(III) signs the logbook and 
                                legibly prints in the logbook his or 
                                her name, address, and the date and 
                                time of the sale; and
                            ``(ii) the person determines that the name 
                        signed and printed in the logbook corresponds 
                        to the name provided on such identification and 
                        that the date and time entered are correct.
                    ``(G) The person maintains possession of each 
                logbook for not fewer than two years after the date of 
                the last sale entered in the logbook.
                    ``(H) The person does not offer a promotion in 
                which, as part of a purchase transaction, such a 
                product is provided without charge.
                    ``(I) On the premises of the location involved, the 
                person posts a clear and conspicuous notice providing 
                as follows: `Federal law prohibits the over-the-counter 
                purchase of more than one product containing 
                pseudoephedrine in a 24-hour period, and prohibits the 
                over-the-counter purchase of more than 7,500 milligrams 
                of pseudoephedrine within a 30-day period. If you make 
                an over-the-counter purchase of such a product, you are 
                required to sign a logbook that may be accessible to 
                law enforcement officers.'
            ``(2) Authority to require certain reports.--
                    ``(A) In general.--With respect to each person who 
                manufactures a list I pseudoephedrine product, or who 
                distributes such a product (including a sale at 
                retail), the Attorney General may by regulation require 
                the person to report to the Attorney General--
                            ``(i) any uncommon method of payment or 
                        delivery, or any other circumstance that the 
                        person believes may indicate that the product 
                        will be used in violation of this title;
                            ``(ii) any proposed transaction with an 
                        individual or organization whose description or 
                        other identifying characteristic the Attorney 
                        General furnishes in advance to the person; and
                            ``(iii) any unusual or excessive loss or 
                        disappearance of supplies of the product that 
                        are under the control of the person.
                    ``(B) Additional reports for manufacturers and 
                distributors at wholesale.--With respect to each person 
                who manufactures a list I pseudoephedrine product, or 
                who distributes such a product at wholesale, the 
                Attorney General may by regulation require the person 
                to report to the Attorney General any transaction 
                involving an extraordinary quantity of the product.
                    ``(C) Certain regulations.--Regulations under 
                subparagraphs (A) through (C) of subsection (b)(1) 
                apply to subparagraphs (A) and (B) of this paragraph to 
                the extent that the provisions of such subparagraphs of 
                subsection (b)(1) are identical to the provisions of 
                such subparagraphs of this paragraph. Subparagraphs (A) 
                and (B) of this paragraph do not require the Secretary 
                to promulgate regulations with respect to such 
                identical provisions.
                    ``(D) Relation to certain exemption.--Subparagraphs 
                (A) and (B) apply notwithstanding the exemption for 
                list I pseudoephedrine products under section 
                102(39)(A)(iv)(II).
            ``(3) Removal of exception regarding status as list i 
        chemical.--
                    ``(A) In general.--If the Attorney General 
                determines that list I pseudoephedrine products are 
                being diverted for use in the illicit production of 
                methamphetamine, the Attorney General may by regulation 
                remove the exception under schedule V(c).
                    ``(B) Relation to section 204.--The authority 
                established for the Attorney General under subparagraph 
                (A) is in addition to the authority under section 204. 
                The Attorney General may apply such section in lieu of 
                applying subparagraph (A).''.

SEC. 4. REQUIREMENTS REGARDING SCHEDULE V METHAMPHETAMINE-RELATED 
              PRODUCTS.

    (a) In General.--Section 303 of the Controlled Substances Act (21 
U.S.C. 823) is amended by adding at the end the following subsection:
    ``(i) With respect to schedule V methamphetamine-related products 
that do not require prescriptions, a registration under this section 
for a pharmacy shall provide that, for the general physical location 
involved, the registration is subject to the condition that a sale of 
such a product at retail be made in accordance with the same 
requirements as apply under subparagraphs (B) through (I) of section 
310(d)(1) for the sale at retail of list I pseudoephedrine products.''.
    (b) Conforming Amendment.--Section 201(g)(1) of the Controlled 
Substances Act (21 U.S.C. 811(g)(1)), as amended by section 2(b)(1) of 
Public Law 108-358 (118 Stat. 1663), is amended--
            (1) by striking ``titles II and III of the Comprehensive 
        Drug Abuse Prevention and Control Act (21 U.S.C. 802 et seq.)'' 
        and inserting ``this title and title III''; and
            (2) by adding at the end the following: ``The preceding 
        sentence does not apply to controlled substances specified in 
        schedule V(b).''.
    (c) Definitions.--Section 102 of the Controlled Substances Act (21 
U.S.C. 802) is amended--
            (1) by redesignating paragraph (46) (as amended by section 
        2(b)(2)(C) of this Act) as paragraph (47); and
            (2) by inserting after paragraph (45) the following 
        paragraph:
    ``(46)(A) The term `schedule V methamphetamine-related product' 
means a product that is approved under section 505 of the Federal Food, 
Drug, and Cosmetic Act and--
    ``(i) contains ephedrine or phenylpropanolamine; or
    ``(ii)(I) contains pseudoephedrine; and
    ``(II) is not a list I pseudoephedrine product.
    ``(B) The term `schedule V pseudoephedrine product' means a product 
described in subparagraph (A) to which clause (ii) of such subparagraph 
applies.''.

SEC. 5. ENFORCEMENT.

    (a) Sales at Retail of Methamphetamine-Related Products.--
            (1) In general.--Section 402 of the Controlled Substances 
        Act (21 U.S.C. 842) is amended--
                    (A) in subsection (a)--
                            (i) in paragraph (5), by inserting ``, 
                        other than section 310(d)(2)'' before the 
                        semicolon;
                            (ii) in paragraph (10), by striking 
                        ``section 310; or'' and inserting ``section 
                        310, other than subsection (d)(2);'';
                            (iii) in paragraph (11), by striking the 
                        period at the end and inserting a semicolon; 
                        and
                            (iv) by inserting after paragraph (11) the 
                        following paragraphs:
            ``(12) who is a retail distributor to knowingly or 
        negligently sell at retail a list I pseudoephedrine product in 
        violation of a requirement under section 310(d)(1), or who is a 
        manufacturer or distributor (retail or wholesale) to fail to 
        submit a report regarding such a product that is required under 
        section 310(d)(2) or regulations under such section; or
            ``(13) who is a pharmacy or pharmacist registered under 
        section 303(f) to knowingly or negligently sell at retail a 
        schedule V methamphetamine-related product in violation of any 
        requirement under section 303(i);''; and
                    (B) in subsection (c)(1)(B), by inserting before 
                the period the following: ``, except that this 
                subparagraph does not apply to a violation of 
                subsection (a) or (b) of section 310 with respect to a 
                list I pseudoephedrine product by a person who is not a 
                retail distributor''.
            (2) Conforming amendments.--Section 401 of the Controlled 
        Substances Act (21 U.S.C. 841) is amended--
                    (A) in subsection (b)(3), in the first sentence, by 
                inserting after ``shall'' the following: ``, except to 
                the extent that section 402(a)(13) applies,''; and
                    (B) in subsection (f)--
                            (i) in paragraph (1), by inserting after 
                        ``shall'' the following: ``, except to the 
                        extent that section 402(a)(12) applies,''; and
                            (ii) in paragraph (2), by inserting ``, 
                        other than subsection (d)(2),'' after ``section 
                        310''.
    (b) Restrictions on Retail Purchases of Pseudoephedrine Products; 
Violation of Logbook Requirements for Methamphetamine-Related 
Products.--Section 404(a) of the Controlled Substances Act (21 U.S.C. 
844(a)) is amended by inserting after the second sentence the 
following: ``It shall be unlawful for any person to knowingly or 
intentionally purchase at retail without a prescription more than one 
schedule V or list I pseudoephedrine product during a 24-hour period, 
or more than 7,500 milligrams of pseudoephedrine in such products 
during a 30-day period, or to knowingly or intentionally purchase a 
schedule V methamphetamine-related product or a list I pseudoephedrine 
product without signing the appropriate logbook and printing 
information in accordance with section 310(d)(1)(F)(i)(III) or 
303(i).''.
    (c) Controlled Substances; Unauthorized Manufacturing-Related 
Possession or Distribution of Ephedrine, Pseudoephedrine, or 
Phenylpropanolamine; Distribution in General.--Section 401 of the 
Controlled Substances Act (21 U.S.C. 841) is amended--
            (1) in subsection (b)(3) (as amended by subsection 
        (a)(2)(A) of this section), in the first sentence, by inserting 
        ``subsection (g) or'' before ``section 402(a)(13)'' ; and
            (2) by adding at the end the following:
    ``(g)(1) Any person who possesses a controlled substance specified 
in schedule V(b) with intent to manufacture a controlled substance 
except as authorized by this title, or who possesses, distributes, or 
dispenses such a substance knowing, or having reasonable cause to 
believe, that the substance will be used to manufacture a controlled 
substance except as authorized by this title, shall be sentenced in 
accordance with the same provisions as apply under subsection (c).
    ``(2) Any person who knowingly distributes or dispenses a 
controlled substance specified in schedule V(b) in violation of this 
title shall, except to the extent that section 402(a)(13) applies, be 
fined under title 18, United States Code, or imprisoned not more than 5 
years, or both.''.

SEC. 6. IMPORTS.

    Section 1002(a) of the Controlled Substances Import and Export Act 
(21 U.S.C. 952(a)) is amended--
            (1) in the heading for the section, by adding at the end 
        the following: ``and ephedrine, pseudoephedrine, and 
        phenylpropanolamine'';
            (2) in the matter preceding paragraph (1), by inserting 
        ``or ephedrine, pseudoephedrine, or phenylpropanolamine,'' 
        after ``schedule III, IV, or V of title II,''; and
            (3) in paragraph (1), by inserting ``, and of ephedrine, 
        pseudoephedrine, and phenylpropanolamine, '' after ``coca 
        leaves''.

Meth Lab Eradication Act - Amends the Controlled Substances Act to transfer ephedrine, pseudoephedrine, and phenylpropanolamine to schedule V. Excepts pseudoephedrine contained in a product that: (1) is in the form of a liquid, liquid capsule, or liquid-filled gel capsule; (2) does not contain more than 360 milligrams of pseudoephedrine; and (3) is approved under the Federal Food, Drug, and Cosmetic Act.

Revises the definition of "regulated transaction" to exclude specified transactions involving drugs or products that the Attorney General determines are being diverted for illicit purposes. Repeals a provision requiring the Attorney General to reinstate an exemption with respect to a particular ephedrine, pseudoephedrine, or phenylpropanolamine drug product upon determining that the product is manufactured and distributed in a manner that prevents diversion.

Places restrictions on the sale of list I pseudoephedrine products and schedule V methamphetamine-related products. Requires a person selling list I products to: (1) place the products where the customers do not have direct access to them; (2) maintain a sales logbook that identifies the products, purchasers, dates, and times of sales; (3) not sell such products to persons under age 18; and (4) post on the premises a clear and conspicuous notice stating that federal law prohibits the over-the-counter purchase of more than one product containing pseudoephedrine in a 24-hour period or of more than 7,500 milligrams of pseudoephedrine within a 30-day period.

Sets penalties for violations of this Act.

Amends the Controlled Substances Import and Export Act to prohibit (with exceptions) the importation of ephedrine, pseudoephedrine, and phenylpropanolamine.